ELISA, Western Blotting (WB), Immunohistochemistry (IHC), Immunocytochemistry (ICC), Immunofluorescence (IF)
Aufreinigung
VISTA Antibody is affinity chromatography purified via peptide column.
Immunogen
VISTA antibody was raised against a peptide corresponding to 15 amino acids near the carboxy terminus of human VISTA. The immunogen is located within the last 60 amino acids of VISTA.
VISTA
Reaktivität: Maus
ICFC
Wirt: Armenischer Hamster
Monoclonal
MH5A
FITC
Applikationshinweise
VISTA antibody can be used for Immunohistochemistry at 2 μ,g/mL. For Immunoflorescence start at 20 μ,g/mL. For Immunocytochemistry start at 1 μ,g/mL.
Antibody validated: Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
1 mg/mL
Buffer
VISTA Antibody is supplied in PBS containing 0.02 % sodium azide.
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
-20 °C,4 °C
Informationen zur Lagerung
VISTA antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Target
VISTA
(V-type immunoglobulin domain-containing suppressor of T-cell activation (VISTA))
The lymphocyte activation gene-3 (LAG3) is a member of the immunoglobulin superfamily and binds MHC class II with high affinity (1), negatively regulating T-cell function and homeostasis (2). It is expressed in B, T, and NK cells, monocytes, and dendritic cells (3), and acts to regulate T cell expansion (4). LAG3 is also an important immune checkpoint protein, with anti-LAG3 antibodies activating T effector cells and affecting regulatory T cell functions. Furthermore LAG3 appears to act in a synergistic fashion with PD-1/PD-L1, suggesting that a dual antibody approach may prove useful in cancer immunotherapy (5).